Chimeric antigen receptor (CAR) T-cell therapy may be a novel treatment but it is a therapy that is very deliverable, says Dr Michael Dickinson, Clinical Haematologist at the Peter MacCallum Cancer Centre in Melbourne. In a follow-up to the CAR-T Connect medical education event hosted by Novartis in August, the limbic spoke with Dr Dickinson ...
Preparing patients with DLBCL for CAR T-cell therapy
20 Nov 2020
Sponsored by Novartis Pharmaceuticals Australia Pty Limited